Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

Summary

  • The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments.
  • Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025.
  • The bar for plozasiran is set by Ionis' olezarsen in terms of APOC3 and triglyceride reductions as well as the reduction in the risk of acute pancreatitis.
  • Plozasiran in FCS represents a small but important step for Arrowhead's cardiometabolic pipeline which is set to expand later this year with the addition of two new clinical candidates.
  • ARWR needs to do a better job managing expectations or executing on its promised timelines.
  • Looking for a portfolio of ideas like this one? Members of Growth Stock Forum get exclusive access to our subscriber-only portfolios. Learn More »

A group of arrows moving up and around obstacles

Richard Drury/DigitalVision via Getty Images

Arrowhead Pharmaceuticals Overview

The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR). I argued in late 2023 that the company needed to address the financing overhang, and it did just

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

9.2K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ARWR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ARWR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ARWR

Related Stocks

SymbolLast Price% Chg
ARWR
--